LIGAND Pharmaceuticals executive Andrew Reardon sold 5,000 shares across five open-market transactions priced from $283.99 to $288.98 per share. He retained 36,514 shares afterward, giving investors a disclosed view of his remaining position and the scale of the sale relative to his post-transaction holdings.

Key Highlights

  • The transactions took place on 3 September 2026.
  • All five sales used SEC transaction code S.
  • Reardon sold 5,000 shares at prices ranging from $283.99 to $288.98 per share.

LIGAND PHARMACEUTICALS INC (NASDAQ: LGND) executive Andrew Reardon sold 5,000 shares at prices ranging from $283.99 to $288.98 per share. The CLO and secretary completed the transactions across five sales, retaining 36,514 shares afterward.

Five Sales on 3 September 2026

All five transactions occurred on 3 September 2026. Each used SEC transaction code S. The filing identifies Reardon as LIGAND’s CLO and secretary. The reported per-share prices started at $283.99 and extended to $288.98. The combined activity covered 5,000 shares across the five separate transactions. Reardon’s ownership stood at 36,514 shares following the transactions.